In this study, age, sex, recurrence, metastasis, death rate, and histologic patterns were in agreement with those of previous reports on canine mast cell tumors. Histologic grading, mitotic index, chromosome nucleolar organizer regions stained with silver (AgNORs), and anti-proliferating cell nuclear antigen (PCNA) were evaluated as indicators of prognosis. Histologic grading, AgNORs estimated in 100 cells, and PCNA-labeled fraction estimated in five high power fields (HPFs) were significantly different between recurring and nonrecurring tumors. Those prognostic factors were also significantly different between tumors that metastasized and those that did not. The survival time was lower in dogs with mast cell tumors with histologic grade 3 (Patnaik's), AgNOR counts higher than 2.25, and PCNA count in five HPFs higher than 261. The significance of these factors as markers for prognosis determined by logistic regression analysis differed with the time period considered. By combining the three most significant prognostic factors in a prognostic index, three models were obtained to determine the probability of nonrecurrence at 3, 6, and 9 months after surgery. The models were accurate in the prediction of the outcome of up to 80% of mast cell tumors. The use of these models provides a less subjective means of prognosticating mast cell tumors than the use of any one component alone.
AylRDCoutoCGHammerASWeisbrodeSReicsonJGMathesL:
Correlation of DNA ploidy to tumor histologic grade, clinical variables, and survival in dogs with mast cell tumors.
Vet Pathol29:
386–390,
1992.
2.
BostockDE:
The prognosis following surgical removal of mastocytomas in dogs.
J Small Anim Pract14:
27–40,
1973.
3.
BostockDECrockerJHarrisKSmithP:
Nucleolar organizer regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours.
Br J Cancer59:
915–918,
1989.
4.
BravoRFrankRBlundellPAMacDonald-BravoH:
Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ.
Nature326:
515–520,
1987.
5.
BravoRMacDonald-BravoH:
Existence of two populations of cyclin/proliferating cell nuclear antigen during cell cycle: association with DNA replication sites.
J Cell Biol105:
1549–1554,
1987.
6.
ChambersF:
The incidence of cancer in domestic animals.
Vet Rec18:
709–712,
1931.
7.
CrockerJBoldyDAREganMJ:
How should we count AgNORS? Proposal for a standardized approach.
J Pathol158:
185–188,
1989.
8.
DerenziniMPessionATrereD:
Quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells.
Lab Invest63:
137–140,
1990.
9.
ErJCSuttonRH:
A survey of skin neoplasms in dogs from the Brisbane region.
Aust Vet J66:
225–227,
1989.
10.
FieldingLPHensonDE:
Multiple prognostic factors and outcome analysis in patients with cancer.
Cancer71:
2426–2429,
1993.
11.
GarridoMCCordellJLBeckerMHGKeyGGerdesJJonesMGatterKCMasonDY:
Monoclonal antibody JC12: new reagent for studying cell proliferation.
J Clin Pathol45:
860–865,
1992.
12.
GrossTLIhrkePJWalderEJ:
Histiocytic and mast cell tumors.
In:
Veterinary Dermatology,
ed. ReinhardtRW,
1st ed.,
pp. 465–473.
Mosby Year Book,
St. Louis, MO,
1992.
13.
HallPALevisonDAWoodsALYuCCWKellockDBWatkinsJABarnesDMGillettCECamplejohnRDoverRWassemNHLaneDP:
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.
J Pathol162:
285–294,
1990.
14.
HottendorfGHNielsenSW:
Pathologic survey of 300 extirpated canine mastocytomas.
Zentralbl Veterinärmed Reihe A14:
272–281,
1967.
15.
HottendorfGHNielsenSW:
Pathologic report of 29 necropsies on dogs with mastocytoma.
Pathol Vet5:
102–121,
1968.
16.
JonesCJPMosleySMJeffreyIJMStodartRW:
Elimination of the nonspecific binding of avidin to tissue sections.
Histochem J19:
264–268,
1987.
17.
KamelOWBrunDPLDavisREBerryGJWarnkeRA:
Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A2.
Am J Pathol138:
1471–1477,
1991.
18.
LarssonB:
Some aspects of canine mastocytoma.
Nord Veterinärmed9:
241,
1957.
19.
MagnolJPToulemondeN:
Histoprognostic du mastocytomecanin. Validité du grading de Patnaik.
Rev Méd Vét (Toulouse)138:
125–129,
1987.
20.
McCormickDHallPA:
The complexities of proliferating cell nuclear antigen.
Histopathology21:
591–594,
1992.
21.
MisdorpW:
Incomplete surgery, local immunostimulation, and recurrence of some tumour types in dogs and cats.
Vet Q9:
279–286,
1987.
22.
MiyachiKFritzlerMJTanEM:
Autoantibody to a nuclear antigen in proliferating cells.
J Immunol121:
2228–2234,
1978.
NielsenSWColeCR:
Canine mastocytoma. A report of one hundred cases.
Am J Vet Res19:
417–432,
1958.
25.
OgataKKurkiPCelisJENakamuraRMTanEM:
Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication.
Exp Cell Res168:
475–486,
1987.
26.
O'KeefeDA:
Canine mast cell tumors.
Vet Clin North Am (Small Anim Pract)20:
1105–1115,
1990.
27.
OliverJBloomFMangieriC:
On the origin of heparin.
J Exp Med86:
107–116,
1947.
28.
PatnaikAKEhlerWJMacEwenEG:
Canine mast cell tumor: morphologic grading and survival time in 83 dogs.
Vet Pathol21:
469–474,
1984.
29.
PetersJE:
Canine mastocytoma excess risk as related to ancestry.
J Natl Cancer Inst42:
435–443,
1969.
30.
PlotonDMenagerMJeannessonPHimberGPigeonFAdnettJJ:
Improvement in the staining and in the argylophilic protein of the nucleolar organizer region at the optical level.
Histochem J18:
5–14,
1986.
31.
QuinnCMWrightNA:
The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables.
J Pathol160:
93–102,
1990.
32.
RogersKS:
Common questions about diagnosing and treating canine mast cell tumors.
Vet Med88:
246–250,
1993.
33.
RothwellTLWHowlettCRMiddletonDJGriffithsDADuffBC:
Skin neoplasms of dogs in Sydney.
Aust Vet J64:
161–164,
1987.
34.
SiitonenSMKallioniemiOPIsolaJJ:
Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has impact in archival paraffin-embedded node-negative breast cancer.
Am J Pathol142:
1081–1089,
1993.
35.
SmithFGMurrayPGCrockerJ:
Correlation between PCNA and AgNOR scores in non-Hodgkin's lymphomas using sequential staining technique.
J Clin Pathol46:
28–31,
1993.
36.
StartRDCrossSSClellandCSilcocksPBRogersKSmithJH:
Delay in fixation does not affect the immunoreactivity of proliferating cell nuclear antigen.
J Pathol168:
197–199,
1992.
37.
TheuniseenPHMHLeersMPGBollenECM:
Proliferating cell nuclear antigen (PCNA) expression on formalin fixed tissue of non-small cell lung carcinoma.
Histopathology20:
251–255,
1992.
38.
TungekarMFGatterKCDunnillMSMasonDY:
Ki67 immunostaining and survival in operable lung cancer.
Histopathology19:
545–550,
1991.
39.
VisakorpiT:
Proliferative activity determined by DNA flow cytometry and proliferative cell nuclear antigen (PCNA) immunochemistry as a prognostic factor in prostatic carcinoma.
J Pathol168:
7–13,
1992.
40.
WeissE:
Morphologie und formale Genese der Neubildung der Zellen des Retothelialen Systems (RS) bei Hund und Katze.
Zentralbl Veterinärmed9:
437–462,
1962.
41.
YuCCWFletcherCDMNewmanPLGoodladJRBurtonJCLevisonDA:
A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours.
J Pathol166:
147–152,
1992.
42.
ZimmerCGottschalkJNavarroJCWMartinHBeilMJautzkeG:
Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas.
Pathol Res Pract188:
951–958,
1992.
